Jacob Plieth
@JacobPlieth
Journalist @ ApexOnco. The Wolverine Of Biotech / Mr ASH. Once had a blue tick. Interested in: oncology. Not interested in: what stock you bought today.
$JANX resurrects a TROP2 asset, and continues tinkering with CD28. Meanwhile, JANX007 & JANX008 data are a waiting game. Via @ApexOnco -> oncologypipeline.com/apexonco/node/… $CTMX
So about $JANX introducing a TROP2 project to the pipeline... here's what it said in its S-1 in 2021
5,000 patients later $RHHBY finally dumps its #tigit (Sky-14 is quietly said to have failed). Via @ApexOnco -> oncologypipeline.com/apexonco/node/… $RCUS $GILD $AZN
If you were puzzled by Scancell's subgroup data reveal yesterday you weren't alone. @ByMadeleineA tried to get to the bottom of the story on @ApexOnco -> oncologypipeline.com/apexonco/node/… $SCLP.L
Because it's always scientifically sound to run stats on a dataset designed to show something completely different $SRPT
$srpt so a p value of 0.0016 that distribution of AAVrh47-related deaths random. More generally, most, if not all liver-related AAV deaths have been in patients that had liver issues to start with. If the FDA cant see that, I dont know.
It’s a great example of how much damage you can do by being “kind” Sarepta should have been put out if it’s misery a decade ago. They played on the desperation of families to continue forward with poorly effective approaches. And they are calling on those same desperate parents…
Concentra strikes again. I wonder if $XOMA put in a bid. $ITOS
